CG Oncology, Inc. Common stock
NASDAQ:CGON · NASDAQ Global Select
+$1.35 today
Vol 1.80M · Avg 1.08M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-21.4%
avg -24.0%
ROIC
-25.0%
avg -23.6%
ROA
-20.3%
avg -20.5%
Analysis
ROA is currently the strongest return metric at -20.3% versus its period average of -20.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Arthur Kuan | Chairman, President & CEO | $1.13M | — | 35 | $271,600.00 | 0.31% |
Ambaw Bellete | Chief Operating Officer | $847,791.00 | — | 55 | $107,508.00 | 0.12% |
James DeTore | Chief Financial Officer | $785,472.00 | — | 61 | $2,620.00 | <0.01% |
Vijay Kasturi | Chief Medical Officer | $759,983.00 | — | 58 | $79,216.00 | 0.09% |
Joshua F. Patterson | General Counsel, Chief Compliance Officer & Secretary | $693,819.00 | — | 49 | $45,266.00 | 0.05% |
Bing Kung | Vice President of Corporate Development | — | — | — | — | — |
Swapnil Bhargava | Chief Technical Officer | — | — | — | — | — |
Amy Steele | Vice President of Finance & Administration | — | — | — | — | — |
Sarah Connors | Vice President of Communications & Patient Advocacy | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$50.00M
Sells
24
$7.62M
Net Sentiment
+$42.38M
Net buying
Most Active
Mulay James
13 transactions
1–10 of 25
Analysis
Insiders reported 1 buys worth $50.00M and 24 sells worth $7.62M over the last 12 months. That adds up to net buying of $42.38M. Mulay James was the most active insider with 13 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | +176.6% | +226.9% (5yr)6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Recent growth has been strongest in Revenue at +176.6% over three years. Forward estimates point to Revenue at +226.9% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Centessa Pharmaceuticals plc
NASDAQ:CNTA
$6.16B
Apogee Therapeutics, Inc.
NASDAQ:APGE
$5.54B
Legend Biotech Corporation
NASDAQ:LEGN
$5.43B
Travere Therapeutics, Inc.
NASDAQ:TVTX
$5.09B
Xenon Pharmaceuticals Inc.
NASDAQ:XENE
$4.24B
Celcuity Inc.
NASDAQ:CELC
$4.20B
Disc Medicine, Inc.
NASDAQ:IRON
$2.72B
Ultragenyx Pharmaceutical Inc.
NASDAQ:RARE
$2.72B
Tarsus Pharmaceuticals, Inc.
NASDAQ:TARS
$2.70B
Ascentage Pharma Group International
NASDAQ:AAPG
$398.35M
Who manages CGON?
CG Oncology, Inc. Common stock (CGON) lists 9 active executives. The top listed executive is Ambaw Bellete, Chief Operating Officer.
Are CGON insiders buying or selling?
Recent insider activity shows net buying of $135.81M.
Explore More
Continue the stock analysis
Jump to another research area for this company.